These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20482594)

  • 1. Hydrochloride pioglitazone decreases urinary TGF-beta1 excretion in type 2 diabetics.
    Hu YY; Ye SD; Zhao LL; Zheng M; Chen Y
    Eur J Clin Invest; 2010 Jul; 40(7):571-4. PubMed ID: 20482594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydrochloride pioglitazone decreases urinary monocyte chemoattractant protein-1 excretion in type 2 diabetics.
    Ye S; Zheng M; Hu Y; Wu F; Zhao L; Chen Y
    Diabetes Res Clin Pract; 2010 Jun; 88(3):247-51. PubMed ID: 20371128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of hydrochloride pioglitazone on urinary 8-hydroxy -deoxyguanosine excretion in type 2 diabetics.
    Wang Y; Ye S; Hu Y; Zhao L; Zheng M
    J Diabetes Complications; 2013; 27(1):75-7. PubMed ID: 23021797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pioglitazone hydrochloride monotherapy or in combination with sulfonylurea therapy improves glycemia control in patients with type 2 diabetes].
    Yu Y; Li Y; Fan J; Wang Y; Yu H; Wang C; Liao Z; Gao H; Zhao W
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jan; 34(1):117-20. PubMed ID: 15600200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Podocyte as a potential target of inflammation: role of pioglitazone hydrochloride in patients with type 2 diabetes.
    Xing Y; Ye S; Hu Y; Chen Y
    Endocr Pract; 2012; 18(4):493-8. PubMed ID: 22441004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Kipnes MS; Krosnick A; Rendell MS; Egan JW; Mathisen AL; Schneider RL
    Am J Med; 2001 Jul; 111(1):10-7. PubMed ID: 11448655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone.
    Pareek A; Chandurkar N; Thomas N; Viswanathan V; Deshpande A; Gupta OP; Shah A; Kakrani A; Bhandari S; Thulasidharan NK; Saboo B; Devaramani S; Vijaykumar NB; Sharma S; Agrawal N; Mahesh M; Kothari K
    Curr Med Res Opin; 2014 Jul; 30(7):1257-66. PubMed ID: 24669876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.
    Katavetin P; Eiam-Ong S; Suwanwalaikorn S
    J Med Assoc Thai; 2006 Feb; 89(2):170-7. PubMed ID: 16579002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.
    Derosa G; Mereu R; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Palumbo I; Maffioli P; Randazzo S; Cicero AF
    J Clin Pharm Ther; 2010 Oct; 35(5):565-79. PubMed ID: 20831680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of pioglitazone on type 2 diabetic patients with hemodialysis.
    Abe M; Kikuchi F; Okada K; Kaizu K; Matsumoto K
    Diabetes Res Clin Pract; 2008 Jun; 80(3):432-8. PubMed ID: 18346811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal Outcomes of Pioglitazone Compared with Acarbose in Diabetic Patients: A Randomized Controlled Study.
    Chen YH; Tarng DC; Chen HS
    PLoS One; 2016; 11(11):e0165750. PubMed ID: 27812149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
    Wainstein J; Katz L; Engel SS; Xu L; Golm GT; Hussain S; O'Neill EA; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2012 May; 14(5):409-18. PubMed ID: 22059736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.
    Hanefeld M; Brunetti P; Schernthaner GH; Matthews DR; Charbonnel BH;
    Diabetes Care; 2004 Jan; 27(1):141-7. PubMed ID: 14693980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.
    Miyazaki Y; Mahankali A; Matsuda M; Glass L; Mahankali S; Ferrannini E; Cusi K; Mandarino LJ; DeFronzo RA
    Diabetes Care; 2001 Apr; 24(4):710-9. PubMed ID: 11315836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal function preservation with pioglitazone or with basal insulin as an add-on therapy for patients with type 2 diabetes mellitus.
    Chang YH; Hwu DW; Chang DM; An LW; Hsieh CH; Lee YJ
    Acta Diabetol; 2017 Jun; 54(6):561-568. PubMed ID: 28331986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes.
    Seufert J; Urquhart R
    Diabetes Res Clin Pract; 2008 Mar; 79(3):453-60. PubMed ID: 18160120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.
    Abdul-Ghani M; Migahid O; Megahed A; Adams J; Triplitt C; DeFronzo RA; Zirie M; Jayyousi A
    Diabetes Care; 2017 Mar; 40(3):325-331. PubMed ID: 28096223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes.
    Yamanouchi T; Sakai T; Igarashi K; Ichiyanagi K; Watanabe H; Kawasaki T
    Diabet Med; 2005 Aug; 22(8):980-5. PubMed ID: 16026361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The alpha-lipoic acid decreases urinary podocalyxin excretion in type 2 diabetics by inhibiting oxidative stress in vivo.
    Lin H; Ye S; Xu J; Wang W
    J Diabetes Complications; 2015; 29(1):64-7. PubMed ID: 25312599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections.
    Riddle MC; Rosenstock J; Vlajnic A; Gao L
    Diabetes Obes Metab; 2014 May; 16(5):396-402. PubMed ID: 24118931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.